March 30, 2025 - 15:10

In a significant shakeup within the nation’s health agency, the FDA's leading vaccine official, Dr. Peter Marks, has resigned amid rising tensions. Dr. Marks expressed concerns over Health Secretary Robert F. Kennedy Jr.'s alleged demand for "subservient confirmation" of what he described as misinformation and lies. This resignation comes on the heels of a startling announcement from the Department of Health and Human Services (HHS), which revealed plans to lay off approximately 10,000 workers.
The implications of these developments are profound, as they could hinder the agency's ability to respond effectively to public health challenges. Experts warn that such drastic cuts may lead to a decrease in oversight and support for vital health initiatives, potentially jeopardizing the safety and efficacy of vaccines and other critical health programs. Former HHS leaders have voiced their concerns about the long-term effects on public health infrastructure, emphasizing the need for a stable and informed leadership to navigate ongoing health crises.
July 23, 2026 - 15:06
Good riddance to bundled ‘global’ maternal care billingThe American College of Obstetricians and Gynecologists is welcoming a major shift in how pregnancy and childbirth are billed. For years, the system relied on a single, bundled `global` fee that...
July 22, 2026 - 21:50
West Nile virus found in two mosquito traps in DeKalb County, health officials sayHealth authorities in DeKalb County have confirmed that mosquitoes collected from two separate traps have tested positive for the West Nile virus. The positive samples were identified during...
July 22, 2026 - 08:37
Bradford A&E services downgraded by health watchdogA health watchdog has downgraded the accident and emergency services at Bradford Royal Infirmary following an inspection that uncovered significant concerns. The Care Quality Commission (CQC) found...
July 21, 2026 - 17:42
Rare disease drugmakers try to avoid Trump price cutsPharmaceutical companies that specialize in treatments for rare diseases are scrambling to shield their products from possible price cuts under a potential second Trump administration. During his...